GSK Highlights P-III (DREAMM-8) Study Data of Blenrep Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma at ASCO 2024
Shots:
- The P-III (DREAMM-8) study assessed the safety & efficacy of Blenrep + pomalidomide & dexamethasone (PomDex) vs bortezomib + PomDex in RRMM patients (n=302) who received at least 1L of therapy or had documented disease progression
- The results showed improved PFS with mPFS not attained vs 12.7mos. at 21.8mos. of median follow-up & 71% vs 51% of patients were alive without progression at the end of 1yr. OS evaluation is underway though a trend was seen during the interim analysis
- Furthermore, the study also demonstrated a 77% vs 72% ORR, 9% vs 3% sCR, 31% vs 14% CR, 24% vs 22% VGPR, 14% vs 34% PR, 40% vs 16% CR or better rate, 64% vs 38% VGPR or better rate & 23.9% vs 4.8% MRD negativity rate with mDoR not reached vs 17.5mos.
Ref: GSK | Image: GSK
Related News:- GSK Reports P-III (DREAMM-8) Study Results of Blenrep for Treating Relapsed/Refractory Multiple Myeloma (RRMM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
